Annual report for Zydus Wellness Ltd. for FY-2017
27-05-2017
Schedule Of Analyst Meet
Pursuant to Regulation 30 of the SEBI [Listing Obligations and Disclosure Requirements] Regulations, 2015, we hereby inform that the Company has planned investor interaction through a teleconference call at 10:30 a.m. on Monday, May 29, 2017 for post results Q&A; session.18-05-2017
Board Meeting On May 27, 2017
We hereby inform that the meeting of the Board of Directors of the Company will be held on Saturday, May 27, 2017 to consider apart from other agenda items to approve the audited financial results for the quarter / year ended on March 31, 2017. Further, as per code of conduct for prevention of Insider Trading adopted by the Company under SEBI [Prohibition of Insider Trading] Regulations, 2015, the Trading Window will remain closed from May 17,...29-04-2017
Updates
Please find attached a certificate as required under Regulation 7(3) of SEBI LODR 2015.12-04-2017
Updates
Company shall submit the audited financial results for the financial year ended on March 31, 2017 within 60 days from the end of the financial year instead of submitting the un-audited financial results for the quarter ended on March 31, 2017.11-04-2017
Compliance Certificate By Practicing Company Secretary For The Half Year Ended On March 31, 2017.
Compliance Certificate by Practicing Company Secretary for the half year ended on March 31, 2017.11-04-2017
Statement Of Investor Complaints For The Quarter Ended On March 31, 2017.
Statement of Investor Complaints for the quarter ended on March 31, 2017.11-04-2017
Shareholding for the Period Ended March 31, 2017
Zydus Wellness Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2017. For more details, kindly Click here11-04-2017
Zydus announces settlement with Supernus
Cadila Healthcare Ltd (Zydus Cadila), and its subsidiary Zydus Pharmaceuticals (USA) Inc., a generic pharmaceutical company in the United States, on Tuesday, announced that they have finalised an...08-03-2017
Zydus inks pact with Supernus Pharma to settle patent issue
Cadila Healthcare Ltd (Zydus Cadila), and its subsidiary Zydus Pharmaceuticals (USA) Inc., a generic pharmaceutical company in the United States, on Tuesday, announced that they have finalised an...07-03-2017